Abstract | BACKGROUND: METHODS: Treatment-naive patients from ADVANCE, ILLUMINATE, OPTIMIZE and SPRINT-2, and treatment-experienced patients from RESPOND-2 were included. Multivariable logistic regression analyses were performed to evaluate whether ribavirin concentrations were an independent predictor of sustained virological response or anaemia. Optimal cutoff values and the percentage of patients within the proposed therapeutic range were determined, along with the associated chance of response. RESULTS: Overall, 1,502 patients were included. In both regimens, ribavirin concentrations were significantly associated with anaemia (haemoglobin level <10 g/dl) at all time points (1.75 < odds ratio [OR] <2.45) and sustained virological response was associated with ribavirin concentrations at week 8 (OR=1.43 for telaprevir and 1.78 for boceprevir). A therapeutic range for ribavirin at week 8 of 2.2-3.5 mg/l was defined for telaprevir treatment. Of the 48% of patients with a concentration within this range, 81% achieved sustained virological response and only 5.1% reported anaemia. For boceprevir treatment, the week 8 optimal range was defined as 2.2-3.6 mg/l and 50% of patients had a concentration within this range, of whom 69% achieved sustained virological response and 46% developed anaemia. CONCLUSIONS:
|
Authors | Clara Tmm de Kanter, Maria Buti, Ralph DeMasi, Sivi Ouwerkerk-Mahadevan, Anton Sm Dofferhoff, James Witek, Joost Ph Drenth, Stefan Zeuzem, David M Burger |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 21
Issue 2
Pg. 153-9
( 2016)
ISSN: 2040-2058 [Electronic] England |
PMID | 26378941
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Oligopeptides
- Ribavirin
- telaprevir
- N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
- Proline
|
Topics |
- Anemia
(chemically induced)
- Antiviral Agents
(administration & dosage, therapeutic use)
- Drug Therapy, Combination
- Hepacivirus
(genetics)
- Hepatitis C, Chronic
(drug therapy)
- Humans
- Oligopeptides
(administration & dosage, therapeutic use)
- Proline
(administration & dosage, analogs & derivatives, therapeutic use)
- Ribavirin
(administration & dosage, adverse effects, therapeutic use)
|